This inventor holds 4 USPTO granted patents and 6 published patent applications. Top assignees: Vividion Therapeutics, Inc., Scripps Research Institute. Active years: 2020-2025.
Company Filing History:
4 out of 4 
3 out of 1,203 
Years Active: 2020-2025
Title: The Innovations of Benjamin Horning
Introduction
Benjamin Horning is a notable inventor based in San Diego, CA. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that target specific biological processes. With a total of 4 patents to his name, Horning's work is paving the way for advancements in medical treatments.
Latest Patents
Horning's latest patents include innovative pharmaceutical compositions that comprise WRN helicase inhibitors. These compounds are designed to inhibit WRN helicase, which is useful in treating proliferative diseases such as cancer. Another significant patent involves cereblon modulators, which are compositions and methods for modulating cereblon neosubstrates. These small molecule modulators can be utilized to influence cereblon neosubstrates, showcasing Horning's commitment to advancing therapeutic options.
Career Highlights
Throughout his career, Benjamin Horning has worked with prominent organizations such as Vividion Therapeutics, Inc. and The Scripps Research Institute. His experience in these institutions has allowed him to collaborate with leading experts in the field and contribute to groundbreaking research.
Collaborations
Horning has collaborated with notable colleagues, including David S. Weinstein and Dean Stamos. These partnerships have further enriched his research and development efforts, leading to innovative solutions in the pharmaceutical industry.
Conclusion
Benjamin Horning's contributions to the field of pharmaceuticals through his patents and collaborations highlight his role as an influential inventor. His work continues to inspire advancements in medical treatments and showcases the importance of innovation in addressing complex health challenges.